Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers Health, Inc. (NYSE: HIMS) announced the redemption of all outstanding warrants to purchase Class A common stock. The warrants will be redeemed at $0.10 each if the stock price is at least $10.00 on the trading day before redemption. A notice has been sent to warrant holders, and trading of public warrants will halt on August 6, 2021. Holders can exercise their warrants until 5:00 p.m. on August 9, 2021, either by cash payment of $11.50 or on a cashless basis, which equates to receiving shares based on market value. Unexercised warrants will be void after the redemption date.
Hims & Hers Health, Inc. (NYSE: HIMS) has launched two new product bundles in response to increasing consumer demand for sexual health products. Recognizing that nearly half of consumers engage in more sexual experimentation post-pandemic, the company unveiled the Pleasure Essentials Kit ($119) and the Ultimate ‘O’ Kit ($299). Each kit combines popular products like condoms, lubricants, and vibrators to enhance intimate experiences. Hims & Hers also offers ongoing access to sexual health treatments, including birth control and erectile dysfunction solutions, reinforcing its commitment to accessible health care.
Hims & Hers Health, Inc. (NYSE: HIMS) has finalized its acquisition of Apostrophe, a teledermatology specialist. This strategic move aims to enhance the company's telehealth offerings, providing advanced, personalized dermatology treatments to consumers. The acquisition will strengthen Hims & Hers' dermatology business, with Apostrophe's team and its CEO, Ben Holber, joining Hims & Hers to lead this segment. The financial terms of the deal were not disclosed, but it reflects the company’s commitment to expand its healthcare services.
Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with Urban Outfitters, Inc. (NASDAQ: URBN) to offer personalized health and wellness solutions on urbanoutfitters.com. This collaboration will begin with select Hims products, expanding to include products from the Hers line, addressing skin care, hair loss, sexual health, and supplements. Melissa Baird, COO of Hims & Hers, emphasized the importance of consumer access to quality health products, while Jena Tracey from Urban Outfitters highlighted the synergy between their customer base and the personalized offerings of Hims & Hers.
Hims & Hers Health, NYSE: HIMS, has announced plans to acquire Apostrophe, a teledermatology specialist, enhancing its focus on personalized dermatology services. This strategic move aims to boost Hims & Hers' ability to deliver tailored treatment plans and expand its market presence, particularly among GenZ and Millennial consumers. Apostrophe's established clinical platform and licensed pharmacy in 29 states will facilitate faster, scalable delivery of dermatology treatments. The acquisition is anticipated to close in Q3 2023, with Apostrophe's CEO expected to lead the dermatology division.
Hims & Hers Health (NYSE: HIMS) has launched Minoxidil 5% Foam for both men and women, enhancing its hair regrowth product line. This FDA-approved treatment is clinically-proven to regrow hair in 3 to 6 months and works by increasing blood flow to hair follicles, activating hair growth, and extending the growth phase. The addition of this foam option responds to customer demand for convenient hair loss solutions. Global superstar Jennifer Lopez endorses this launch, emphasizing the importance of personalized self-care.
Hims & Hers Health, Inc. (NYSE: HIMS) has been awarded the title of D-To-C Brand of the Year by Ad Age, recognizing its innovative approach in the telehealth sector. The award highlights Hims & Hers' commitment to personalized health and wellness solutions, particularly during the COVID-19 pandemic. CEO Andrew Dudum emphasized the importance of this recognition among notable brands. The Creativity Awards focus on impactful contributions in marketing, with Hims & Hers being lauded for its consumer-centric model and disruption of traditional healthcare.
Hims & Hers Health announces its strategic acquisition of Honest Health, a UK-based health platform specializing in hair loss products. This deal aims to bolster Hims & Hers' operational capabilities and support its expansion into the UK and Western Europe. Honest Health, founded in 2018, offers innovative health solutions through a partnership with a UK compounding pharmacy. The acquisition is expected to close in the second fiscal quarter of 2021, aligning with Hims & Hers' mission to enhance personalized healthcare experiences for consumers.
Hims & Hers has appointed multi-platinum artist Miley Cyrus as a Creative Advisor. She will collaborate on the Hers line of prescription skincare products, enhancing their marketing efforts. Miley emphasizes the importance of personalized skincare, a sentiment echoed by Co-Founder and CEO Andrew Dudum, who aims to demystify skincare routines for consumers. The company provides telehealth consultations and customizable prescription products, focusing on acne and anti-aging treatments. Established in 2017, Hims & Hers operates across all 50 states, offering accessible healthcare solutions.
Hims & Hers has launched a new Topical Finasteride & Minoxidil Spray, a pill-free treatment for male pattern hair loss. This innovative spray combines 6% minoxidil and 0.1% finasteride to effectively block DHT production and promote hair regrowth. The product addresses customer demand for alternative delivery methods to oral medications, providing a drip-free, easy-to-use option. Customers can access this treatment via a telehealth consultation with a licensed medical professional.